Diminished ovarian reserve can make IVF dosing a difficult conversation. More medication does not necessarily produce more eggs, but minimal stimulation is not universally better either. Expected response, prior cycles, age, cost and burden should guide a plan that offers realistic choices rather than automatic escalation.
Low ovarian reserve can make conventional expectations about egg yield unrealistic. The discussion should distinguish diminished reserve from premature ovarian insufficiency and include age, prior response and reproductive goals.
However, medical experts are increasingly shifting the narrative: an AMH in the “0-point range” is not an absolute barrier; it is a signal to stop competing for quantity and start competing for precision.
AMH and antral follicle count help estimate response. They do not alone measure egg quality or establish that all ovarian function has ended.
More medication is not always more useful
Increasing stimulation cannot create new follicles. The appropriate dose and approach depend on ovarian response, prior cycles and the patient’s priorities.
The Rise of Natural and Minimal Stimulation IVF
In this context, specialists are revisiting Natural Cycle IVF and Minimal Stimulation IVF.
- Natural Cycle IVF: This approach focuses on the single, dominant follicle that the body naturally selects each month. The goal is to capture this oocyte at its most viable moment without attempting to recruit non-responsive, quiescent follicles.
- Lower stimulation: May reduce medication burden in selected circumstances, but does not guarantee the highest-quality egg.
Crucially, these methods are not “guarantees of superior quality.” As Dr. Baek Eun-chan of Bundang Jeil Hospital explains, “Natural selection does not guarantee chromosomal normalcy. The goal of these strategies is not to promise ‘better’ eggs, but to ensure that the few oocytes the body manages to produce are not missed.”
A higher dose may not overcome a limited follicle cohort. Conversely, minimal or natural-cycle approaches should not be promised to produce intrinsically better eggs; their suitability depends on the patient and evidence.
Individualize the decision
Timing and monitoring can inform care, but no protocol can promise that a remaining follicle will yield a viable embryo.
- Biological Nuance: Differentiating between a 38-year-old and a 44-year-old with the same 0.3 AMH reading.
- Cycle-to-Cycle Strategy: Recognizing that some months may require more aggressive stimulus to prompt any response, while others are better suited for natural, low-stress collection.
- Dynamic Response Tracking: Adjusting the protocol based on real-time follicular growth, maturity, and developmental potential of the previous cycle’s embryos.
Individualization includes limits
Discuss likely yield, burden, cost and alternatives. A plan should explain its rationale and acknowledge uncertainty rather than promise that finding the right dose will reverse low reserve.
Continuing IVF, changing approach or stopping are personal decisions to make with realistic counseling. Persistence is an option, not an obligation or a guarantee.
Disclaimer: This report is for informational purposes. Fertility treatment strategies must be highly individualized and determined by a reproductive endocrinologist based on the patient’s specific clinical history.
A dosing discussion grounded in response
The ESHRE guideline discusses stimulation choices for low responders. A low expected yield does not make a particular protocol a guaranteed route to a better egg. ESHRE ovarian stimulation guideline (2025 update).
Related reading
"Controlled Stimulation": Balancing the Precision and Power of Fertility Injections